Investment Analysts’ Recent Ratings Changes for MeiraGTx (MGTX)

MeiraGTx (NASDAQ: MGTX) has recently received a number of price target changes and ratings updates:

• 9/26/2026 – MeiraGTx was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/24/2026 – MeiraGTx is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $16.00 price target on the stock.
• 9/24/2026 – MeiraGTx is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $16.00 price target on the stock.
• 9/22/2026 – MeiraGTx was upgraded by Weiss Ratings from “sell (d-)” to “hold (c)”.
• 9/11/2026 – MeiraGTx was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/15/2026 – MeiraGTx was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/14/2026 – MeiraGTx had its price target raised by Royal Bank Of Canada from $26.00 to $27.00. They now have an “outperform” rating on the stock.
• 8/13/2026 – MeiraGTx was upgraded by Zacks Research from “hold” to “strong-buy”.

Insider Transactions at MeiraGTx

In other news, CEO Alexandria Forbes sold 62,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $13.86, for a total value of $859,320.00. Following the sale, the chief executive officer directly owned 1,325,695 shares of the company’s stock, valued at approximately $18,374,132.70. This represents a 4.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Giroux sold 56,000 shares of MeiraGTx stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $12.51, for a total value of $700,560.00. Following the completion of the transaction, the chief financial officer owned 908,530 shares in the company, valued at approximately $11,365,710.30. The trade was a 5.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.40% of the stock is currently owned by corporate insiders.

MeiraGTx Holdings plc (NASDAQ:MGTX) is a clinical-stage biotechnology company developing gene therapy and ribonucleic acid (RNA) medicines for diseases with significant unmet medical needs. Its research focuses primarily on the central nervous system, immune-mediated conditions and disorders affecting salivary gland function.

The company’s technology platforms are designed to deliver therapeutic genes or regulate gene expression in targeted tissues. Its investigational programs have included gene therapies for Parkinson’s disease and radiation-induced xerostomia, a condition involving chronic dry mouth after cancer treatment.